What are the possible benefits of taking Rubraca (rucaparib) tablets?
Rubraca works when your tumor starts to grow again
The effectiveness of Rubraca (rucaparib) tablets was evaluated in 106 women from 2 clinical studies.
In women with BRCA mutation–positive (BRCAmut+) advanced ovarian cancer who had received at least 2 prior chemotherapy medicines,
As reported by the studies' doctors:
More than half of women saw their tumors shrink with Rubraca treatment
- Rubraca caused tumors to shrink in 54% of patients (95% CI; 44-64)*
- Of the patients who responded to Rubraca, 9% had a complete response and 45% had a partial response. A complete response is not the same thing as a cure
- Not all women saw their tumors shrink or responded to Rubraca treatment
Median† length of response to treatment with Rubraca was 9.2 months
- In women who participated in the rucaparib clinical trials, of those who responded to Rubraca, half showed a response to treatment that was less than 9.2 months while half of the women showed a response that was longer than 9.2 months (95% CI; 6.6-11.6)*
In a separate review by independent doctors not involved in the clinical studies, Rubraca caused tumors to shrink in 42% of patients (95% CI; 32-52).* Of those who responded, half showed a response to treatment that was less than 6.7 months while half of the women showed a response that was longer than 6.7 months (95% CI; 5.5-11.1).*
*There is a 95% chance that the confidence interval (range of numbers or percentages) may include the true mean of all the women in the study.
†Median is a middle point of a range of numbers, half of which are above the middle point, half of which are below it.
BRCA, Breast Cancer susceptibility gene.